Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$84.83 -1.25%

-$1.03 today

Market cap
$4.78B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.89M

Average 0.82M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$129.06M

FY 2025 · Annual

Investing Cash Flow

-$122.83M

FY 2025 · Annual

Financing Cash Flow

$280.13M

FY 2025 · Annual

+9.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.14M)(28.48M)(43.56M)(84.97M)(162.34M)
Depreciation & Amortization2.02M147K355K412K428K
Deferred Income Tax00(661K)00
Stock-Based Compensation01.52M2.9M12.89M22.79M
Change in Working Capital(1.53M)(1.65M)4.86M(351K)16.73M
Accounts Receivables0(4.16M)5.16M0755K
Inventory00000
Accounts Payables(720K)2.28M661K8.19M11.28M
Other Working Capital(806K)229K(959K)(8.54M)4.69M
Other Non-Cash Items11.11M(606K)(762K)(6.17M)(6.67M)
Operating Cash Flow(59.53M)(29.07M)(36.86M)(78.18M)(129.06M)
Capital Expenditures(1.26M)(139K)(110K)(105K)(213K)
Acquisitions (Net)00000
Purchases of Investments(45.31M)(61.68M)(57.42M)(413.71M)(435.01M)
Sales of Investments90M2M77.79M127M312.39M
Other Investing Activities00000
Investing Cash Flow43.43M(59.82M)20.25M(286.81M)(122.83M)
Debt Repayment00000
Common Stock Issued89.6M072M269.2M280.13M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(3.32M)61.57M(13.58M)0
Financing Cash Flow89.6M96.68M133.57M255.62M280.13M
Effect of Forex Changes00000
Net Change in Cash73.5M7.79M116.97M(109.37M)28.23M
Free Cash Flow(60.8M)(29.21M)(36.97M)(78.29M)(129.27M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$162.3M
+ D&A$428.0K
+ Stock-Based Comp$22.8M
+ Deferred Tax$0
+ Working Capital$16.7M
- Other Non-Cash-$6.7M
= Operating Cash Flow-$129.1M
- Capex-$213.0K
= Free Cash Flow-$129.3M

Analysis

FY2025 free cash flow is -$129.3M. FCF conversion is 79.6% of net income. Operating cash flow was -$129.1M, with capex of -$213.0K. The largest bridge item is Stock-Based Comp at $22.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
SC 13GSC 13G filingOct 30, 2026
4Statement of changes in beneficial ownershipSep 18, 2026

Does DNTH generate free cash flow?

Dianthus Therapeutics, Inc. (DNTH) generated -$129.27M of free cash flow in fiscal 2025.

How much operating cash flow does DNTH produce?

Operating cash flow was -$129.06M, before capital expenditures of $213,000.00.